FindTrial
Sign In

PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1

BIOLOGICAL2 trials

Sponsors

Gynecologic Oncology Group

Conditions

Fallopian Tube CarcinomaOvarian Clear Cell CystadenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Seromucinous CarcinomaOvarian Serous CystadenocarcinomaOvarian Undifferentiated CarcinomaPrimary Peritoneal CarcinomaRecurrent Fallopian Tube Carcinoma

Phase 1

EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
CompletedNCT01489371
Gynecologic Oncology GroupOvarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma +5
Start: 2012-07-09End: 2018-01-27Updated: 2019-03-12

Phase 2

EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
CompletedNCT01118052
Gynecologic Oncology GroupFallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma
Start: 2010-11-01End: 2016-07-16Updated: 2018-01-11